It's certainly not looking that way. I'm a little surprised that management hasn't seized the opportunity to announce the final data officially given the additional PR/CR recorded.
What I did find, though, was another co. that presented at the WCCL meeting. Initially, I was startled by the existence of a rival in the field of CTCL. However, Resminostat is described as a "maintenance" therapy and whilst the data seems impressive, the Progression Free duration for those in the placebo group seems exceptionally long.
https://www.4sc.com/product-pipeline/resminostat/
In visiting their website, it appears (if I have interpreted it correctly) that the trial involves patients with less advanced CTCL than what PTX-100 has been treating. PTX-100 has only been tested on patients who have failed between 3 and 6 prior lines of treatment.
https://www.4sc.com/news/4sc-ag-resmain-trial-meets-primary-endpoint-in-cutaneous-t-cell-lymphoma-ctcl/
Not sure what this means: "Given that the RESMAIN study did not meet its key secondary objective, 4SC will now approach the European Medicines Agency in order to better understand the feasibility of submitting a Marketing Authorization Application."
It's certainly not looking that way. I'm a little surprised that...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
